The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Pixelligent Technologies
Advised Pixelligent Technologies, a developer and manufacturer of nanocrystal material used in consumer electronic devices, on a significant strategic investment from Henkel Corporation, a publicly traded (FWB: HEN) German multinational chemical and consumer goods company
INX Software
Advised Tanarra Capital, leading diversified alternative asset investment firm in Australia, on its sale of INX Software, leading end-to-end workforce management and EHS software provider for high-risk, complex and remote businesses, to Accel-KKR
Desktop Metal, Inc.
Advising Nano Dimension, a developer of 3D printing and Additive Manufacturing technologies, predominantly for A&D applications, on its acquisition of Desktop Metal, a vertically integrated 3D printers, materials and software company and pioneer of several 3D printing technologies
Haleon plc’s Nicotine Replacement Therapy Business (ex-US)
Advising Haleon plc on the sale of its global nicotine replacement therapy business (ex-US) to Dr. Reddy’s Laboratories
CP Kelco
Advising Tate & Lyle plc, a UK-listed specialty food and beverage ingredients company, on the acquisition of CP Kelco, a US-based provider of pectin, speciality gums and other nature-based ingredients, from J.M. Huber Corporation
Tegra’s Operating Entities in Honduras, El Salvador, and the U.S.
Advising Tegra, a premier and leading near and onshore apparel manufacturer for sport, team, and performance apparel, on the sale of its operating entities in Honduras, El Salvador, and the U.S. to SAE-A Trading, a vertically integrated textile and apparel garment manufacturer
myHomecare Group
Advising Australian Unity on its acquisition of myHomecare Group
Central nervous system (CNS) portfolio from Sanofi
Advising Pharmanovia, a UK based global lifecycle management healthcare company, on the acquisition of a global central nervous system portfolio from Sanofi, the France based innovative global healthcare company
Clinigen Ltd’s portfolio of Established Medicines
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners
Canopy Growth Corporation
Advised Canopy Growth, a leading diversified cannabis company, on a series of agreements, including privately negotiated redemption agreements with certain holders of its unsecured senior notes due July 15, 2023 and agreements with certain of its lenders under its term loan credit agreement dated March 18, 2021, that will have the overall effect of deleveraging the Company’s balance sheet by ~C$437mm over time
Juice Plus+
Advised Juice Plus+, a global health and wellness company in the direct selling space on a comprehensive recapitalization transaction
Lookers Plc
Advising JerseyCo, the indirect Holdco of Alpha Auto Group, a Canadian automotive dealership group, on its acquisition of Lookers Plc, a leading UK automotive dealership group
Marley Spoon business combination with 468 SPAC II
Advising Marley Spoon SE, an ASX listed global subscription-based meal kit provider, on its business combination agreement with 468 SPAC II, simultaneous capital raising and amendment to existing debt facilities
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
Clinigen Ltd’s Lamda Laboratories
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
Flavor Specialty Ingredients division of IFF
Sole financial adviser to Exponent, one of the UK’s leading private equity firms, on the acquisition of IFF’s Flavor Specialty Ingredients division, a global leader in the base aromas market
Clinigen Ltd’s Proleukin
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
Kyowa Kirin International’s established medicines business
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
Acreage Holdings
Advising Canopy Growth, a leading diversified cannabis company, on the re-organization and consolidation of its U.S. cannabis assets under a new holding company, Canopy USA, and on related investments and debt repurchase transactions
Recipe Unlimited Corporation
Advising the Special Committee of Recipe Unlimited, the largest full-service restaurant company in Canada, on its go private transaction with Fairfax Financial Holdings
UK Operations of Lion Pty Limited
Advised Lion Pty Limited, one of Australasia’s leading beverage companies and a wholly owned subsidiary of Japanese conglomerate Kirin Holdings Co., Ltd., on the divestment of its UK operations to Odyssey Inns Ltd.
Derco Holdings
Advising and acting as sponsor to Inchcape plc, the leading independent global automotive distributor, on its proposed Class 1 acquisition of Derco, the largest independent automotive distributor by volume in Latin America
Theramex
Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners
Acacia Pharma Group plc
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise